Early clinical results from Episealer® Talus study presented at scientific congress
Episurf Medical (Nasdaq: EPIS B) today announces that clinical results for the Episealer® Talus technology have been presented at the 38th Congress of the Italian Foot and Ankle Society in Riva Del Garda, Italy, on September 21-22. The presentation with the title “Episealer Talus, an innovative patient-specific metallic implant for the treatment of osteochondral lesions of the talar dome” was held by Dr Marco Di Ponte from the Rizzoli Orthopedic Institute, Italy, and reported on early results from an investigator-initiated study. The study follows 20 patients who received an Episealer® Talus implant as treatment for an osteochondral defect in the ankle joint.
All patients in the study are followed-up at 3, 6, 12 and 24 months, using the standardised subjective outcome measure Foot and Ankle Outcome Score (FAOS), and the instrument EQ-5D-5L which evaluates the quality of life. The presented results show significant clinical improvements in aggregated FAOS score as well as in quality of life, at a mean follow-up period of 12 months, which is the first available interim data for this study.
“We highly appreciate this study initiative by Prof. Stefano Zaffagnini and his team at the Rizzoli Orthopedic Institute. This is the first results from a prospective study with follow-up of Episealer® Talus patients, and the results indicate a significant potential for our technology, as these lesions are common and often represent a treatment challenge for foot & ankle surgeons. The results also indicate that our positive experiences from our first implant system, the Episealer® Knee, could be valid for other joints”, says Pål Ryfors, CEO, Episurf Medical.
